Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a chinese population

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Zhao, Yangxing ^a   Guo, Shicheng ^b   Sun, Jinfeng ^a   Huang, Zhaohui ^c   Zhu, Tongyu ^b   Zhang, Hongyu ^a   Gu, Jun ^a   He, Yinghua ^a   Wang, Wei ^a   Ma, Kelong ^a   Wang, Jina ^b   Yu, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c Soochow University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER SCREENING; CHINESE; CONTROLLED STUDY; CPG ISLAND; DNA BINDING; DNA DETERMINATION; DNA METHYLATION; DNA SCREENING; ECEL1 GENE; FEMALE; GENE; GENE IDENTIFICATION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; KCNV1 GENE; LMX1A GENE; MAJOR CLINICAL STUDY; MALE; METHYLCAP SEQ; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREDICTIVE VALUE; PROCESS OPTIMIZATION; PROMOTER REGION; PROTEIN DOMAIN; PROX1 GENE; SENSITIVITY AND SPECIFICITY; SLC6A20 GENE; TAL1 GENE; TMEM26 GENE; TUMOR RECURRENCE; URINALYSIS; VALIDATION PROCESS; VAX1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TUMOR; CHINA; DNA METHYLATION; FEMALE; GENOMICS; HOMEODOMAIN PROTEINS; HUMANS; LIM-HOMEODOMAIN PROTEINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84859829499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035175     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Liu E, Xiang Y, Jin F, Zhou S, Sun L, et al. (2004) Cancer incidence trends in urban Shanghai, China (1972-1999). Tumor 24 (1): 11-13.
3. Kaufman D, Shipley W, Feldman A, (2009) Bladder cancer. Lancet 374: 239-249.
4. Mitra A, Cote R, (2009) Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 4: 251-285.
5. Herr H, Lamm D, Denis L, (1997) In Principles and Practice of Genitourinary Oncology. Lippincott Williams & Wilkins pp. 273-280.
6. Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R, (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21: 1315-1330.
7. Berger S, (2007) The complex language of chromatin regulation during transcription. Nature 447: 407-412.
8. Reik W, (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447: 425-432.
9. Feinberg A, (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447: 433-440.
10. Bird A, (1986) CpG-rich islands and the function of DNA methylation. Nature 321: 209-213.
11. Chen R, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R, (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395: 89-93.
12. Eden A, Gaudet F, Waghmare A, Jaenisch R, (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455.
13. Ma Y, Jacobs S, Jackson-Grusby L, Mastrangelo M, Torres-Betancourt J, et al. (2005) DNA CpG hypomethylation induces heterochromatin reorganization involving the histone variant macroH2A. J Cell Sci 118: 1607-1616.
14. Baylin S, (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): S4-11.
15. Baylin S, Ohm J, (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116.
16. Dumache R, David D, Kaycsa A, Minciu R, Negru S, et al. (2011) Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer. Rev Med Chir Soc Med Nat Iasi 115: 163-167.
17. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, et al. (2007) A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13: 7296-7304.
18. Wilhelm-Benartzi C, Koestler D, Houseman E, Christensen B, Wiencke J, et al. (2010) DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis 31: 1972-1976.
19. Reinert T, Mansilla Castano F, Lamy P, Wojdacz T, et al. (2011) Comprehensive genome methylation analysis in bladder cancer; identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res Epub ahead of print.
20. Brinkman A, Simmer F, Ma K, Kaan A, Zhu J, et al. (2010) Whole-genome DNA methylation profiling using MethylCap-seq. Methods 52: 232-236.
21. Kitamura H, Tsukamoto T, (2006) Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol 11: 28-37.
22. Yu J, Zhang H, Ma Z, Lu W, Wang Y, et al. (2003) Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 13: 319-333.
23. Li N, Ye M, Li Y, Yan Z, Butcher L, et al. (2010) Whole genome DNA methylation analysis based on high throughput sequencing technology. Methods 52: 203-212.
24. Li H, Durbin R, (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.
25. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137.
26. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, et al. (2011) Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 20: 1483-1491.
27. Enokida H, Nakagawa M, (2008) Epigenetics in bladder cancer. Int J Clin Oncol 13: 298-307.
28. Rodriguez-Paredes M, Esteller M, (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
29. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, et al. (2010) Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 16: 21-33.
30. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, et al. (2008) Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 98: 466-473.
31. Costa V, Henrique R, Danielsen S, Duarte-Pereira S, Eknaes M, et al. (2010) Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 16: 5842-5851.
32. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, et al. (2010) Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 70: 8169-8178.
33. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, et al. (2006) Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 12: 2109-2116.
34. Friedrich M, Weisenberger D, Cheng J, Chandrasoma S, Siegmund K, et al. (2004) Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 10: 7457-7465.
35. Battagli C, Uzzo R, Dulaimi E, Ibanez de Caceres I, Krassenstein R, et al. (2003) Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 63: 8695-8699.
36. Chan M, Chan L, Tang N, Tong J, Lo K, et al. (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8: 464-470.
37. Tada Y, Wada M, Kuroiwa K, Kinugawa N, Harada T, et al. (2000) MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6: 4618-4627.
38. Negraes P, Favaro F, Camargo J, Oliveira M, Goldberg J, et al. (2008) DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer 8: 238.
39. Versmold B, Felsberg J, Mikeska T, Ehrentraut D, Kohler J, et al. (2007) Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer. Int J Cancer 121 (3): 547-54.
40. Dong W, Feng L, Xie Y, Zhang H, Wu Y, (2011) Hypermethylation-mediated reduction of LMX1A expression in gastric cancer. Cancer Sci 102 (2): 361-6.
41. Cardoso B, de Almeida S, Laranjeira A, Carmo-Fonseca M, Yunes J, et al. (2011) TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells. Leukemia 25 (10): 1578-86.
42. Tsou J, Galler J, Wali A, Ye W, Siegmund K, et al. (2007) DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 58: 220-230.
43. Bharti K, Gasper M, Bertuzzi S, Arnheiter H, (2011) Lack of the ventral anterior homeodomain transcription factor VAX1 leads to induction of a second pituitary Development. 138 (5): 873-8.
44. Ebihara M, Ohba H, Kikuchi M, Yoshikawa T, (2004) Structural characterization and promoter analysis of human potassium channel Kv8.1 (KCNV1) Gene 325: 89-96.
45. Benoit A, Vargas M, Desgroseillers L, Boileau G, (2004) Endothelin-converting enzyme-like 1 (ECEL1) is present both in the plasma membrane and in the endoplasmic reticulum. Biochem J 380(Pt 3): 881-8.
46. Town L, McGlinn E, Davidson T, Browne C, Chawengsaksophak K, et al. (2011) Tmem26 is dynamically expressed during palate and limb development but is not required for embryonic survival. PLoS One. 2011; 6 (9): e25228.